Pyridine → 3,4-dichloro-N-[1-[6-chloro-4-[(E)-N-hydroxy-C-methylcarbonimidoyl]-2-pyridinyl]piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide
반응식
[C:1]([C:4]1[CH:9]=[C:8]([Cl:10])[N:7]=[C:6]([N:11]2[CH2:16][CH2:15][CH:14]([NH:17][C:18]([C:20]3[NH:21][C:22]([CH3:27])=[C:23]([Cl:26])[C:24]=3[Cl:25])=[O:19])[CH2:13][CH2:12]2)[CH:5]=1)(=O)[CH3:2].N1C=CC=CC=1.Cl.[NH2:35][OH:36]>CCO>[Cl:25][C:24]1[C:23]([Cl:26])=[C:22]([CH3:27])[NH:21][C:20]=1[C:18]([NH:17][CH:14]1[CH2:15][CH2:16][N:11]([C:6]2[CH:5]=[C:4](/[C:1](=[N:35]/[OH:36])/[CH3:2])[CH:9]=[C:8]([Cl:10])[N:7]=2)[CH2:12][CH2:13]1)=[O:19]참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
N-[1-(4-Acetyl-6-chloropyridin-2-yl)piperidin-4-yl]-3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamide (Example 115) (49 mg, 0.114 mmol) was dissolved in EtOH (2 ml). Pyridine (74 μl, 0.913 mmol) was added followed by hydroxylamine hydrochloride (63.4 mg, 0.913 mmol). The mixture was stirred at room temperature overnight. The product was purified by semi-prep reverse phase HPLC eluting with CH3CN/H2O (0.1% TFA). (28 mg).
후처리
- customThe product was purified by semi-prep reverse phase HPLC
- washeluting with CH3CN/H2O (0.1% TFA)
출처 및 근거
- ORD 기록
- ord-89c109adcfb543afa89abb601fc4d102
- 출처 데이터셋
- uspto-grants-2010_05
- 특허 번호
- US07709503B2
반응 노트
불러오는 중…